The Innovative Medicines Initiative – Promoting Collaboration for Alzheimer’s Disease Research

Elisabetta Vaudano, IMI Principal Scientific Manager
EP Alzheimer's Collaboration Roundtable, 8 November 2016
Innovative Medicines Initiative: Europe’s partnership for health

A partnership between EU Commission and the European Federation of Pharmaceutical Industries and Association (EFPIA)

Focus on unmet needs
Non-competitive collaborative research
Competitive Calls for proposals
Open collaboration in public-private consortia
Data sharing, dissemination of results...
Industry contribution is in kind
**Why do we need IMI?**

Because drug development is very...

- **complex**
- **risky**
- **inefficient**
- **lengthy**
- **expensive**

Because...

- Biological mechanisms underlying disease are complex
- Clinical trial designs need to be adapted to scientific knowledge
- Regulatory pathways should be adapted due to scientific drivers
Why do we need IMI?

Because despite excellent research we still don’t have…

- enough antibiotics in development
- a cure for diabetes
- an Ebola vaccine
- a cure for schizophrenia
- a cure for dementia

So IMI is…

- supporting projects across the whole spectrum of medical research, development & innovation, including drug development based on understanding the underlying mechanisms of disease
- identifying & developing potential diagnostics and drugs
- testing safety / efficacy
- adapting clinical trial design based on current scientific knowledge
An international, cross-sector community

- 970 academic teams
- 202 SME teams
- 552 EFPIA teams
- 31 patient orgs
- 108 other teams

Over 9 000 researchers working for:
- open collaboration
- improved R&D productivity
- innovative approaches to unmet medical needs

Figures from June 2016
IMI budget breakdown

- Drug Discovery
- Drug safety
- Stem cells
- Data Management
- Cancer
- Inflammatory disorders
- Biologics
- Geriatrics
- Vaccines
- Education and Training
- Lung diseases
- Sustainable chemistry
- Drug delivery
- Drug kinetics
- Other
- Infectious diseases
- Metabolic disorders
- Brain disorders

Figures from May 2016
Antimicrobial resistance – a growing threat

25 000 killed
€1.5 billion

Annual costs of AMR in Europe
IMI New Drugs for Bad Bugs programme

Challenge 1: Getting the drug into the bug

TRANSLOCATION: Addressing scientific challenge of penetration barriers & efflux in & from the pathogen

Challenge 2: Translation from early discovery to clinic

ENABLE: Combine academia / industry expertise to work on early-stage novel molecules

Challenge 3: Clinical dvpt long, costly & often inefficient

COMBACTE family, iABC: Sustainable clinical investigator / laboratory / epidemiology networks; clinical studies incl. in eastern & southern Europe

Challenge 4: Low return on investment

DRIVE-AB: Options for a new economic model of antibiotic development & stewardship. Buy in from stakeholders
Alzheimer’s disease – a major unmet need

Alzheimer’s disease in numbers…

- 46.8 million affected globally
- 10.5 million in Europe
- Global cost EUR 732 billion
Dementia research FP7 (2007-2013)

Collaborative research / Frontier research / Training and mobility

- Research Resources
- Care
- Epidemiology
- Translational and clinical research
- Diagnosis and Monitoring
- Prevention
- Pathophysiology

€50M, €100M, €150M, €200M, €250M

- €584M
- 291 projects
Large number of competitive initiatives

NIH
NCATS
FNIH
FDA
CPI
Accelerating Medicines Partnership
Congressionally directed medical research programmes
US Department of Defense
EU Funding
JTIs - IMI
ERANETS
H2020 competitive calls
EUREKA – funding for technology
COST – R&I networks
EU-backed loans
Global Health Innovation and Technology Fund, Japan
National Funding
National PPPs
Facilitate collaboration to help deliver results faster, create efficiencies and create value
IMI Alzheimer’s Research Platform and beyond
IMI action on Alzheimer’s disease
The world is currently staring at a rapidly advancing future that features 135 million-plus people living with AD or other dementias, costing trillions to care for and treat with no solution in sight.

To significantly advance progress in this area it is necessary to leverage resources and learnings by collaboration and data sharing.

- We will present some examples of how this can be achieved from the IMI projects EMIF, EPAD and AETIONOMY and from the HBP and Dementia Platform UK.
- We will gather the views of different stakeholders on why collaboration is needed, where is the impact and what are the obstacles.
- We will propose some suggestions to facilitate collaborative research in Alzheimer’s disease and other dementias.
Stay in touch

- Visit our website www.imi.europa.eu
- Sign up to our newsletter bit.ly/IMInewsletter
- Follow us on Twitter @IMI_JU
- Join our LinkedIn group bit.ly/LinkedInIMI
- E-mail us infodesk@imi.europa.eu